X4 Pharmaceuticals (XFOR) Misses Q4 EPS by 56c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q4 EPS of ($1.24), $0.56 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Raymond James cuts Delta and JetBlue ratings ahead of Q2 earnings
• IP Strategy reports June validator results with 200,651 $DATA tokens earned
• Hawaiian Electric (HE) PT Lowered to $11.75 at Jefferies